| abstract |
The present invention relates to a combination comprising (a) a cyclooxygenase-2 inhibitor (“COX-2 inhibitor”) and (b) a histone deacylase inhibitor (“HDAI”), in particular a premalignant colon lesion or in a mammal, particularly a human. The present invention relates to a combination that is used individually, sequentially or sequentially for the treatment of colorectal cancer or other malignant tumors. The invention also relates to pharmaceutical compositions comprising such combinations and methods of treating premalignant colon lesions (eg, polyps) and colon cancer and other malignancies in mammals, particularly humans, with such combinations. The invention further relates to a commercial package or product comprising such a combination. |